These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 30076246)
1. Validation of the Semiautomatic Quantification of Brito AE; Mourato F; Santos A; Mosci C; Ramos C; Etchebehere E J Nucl Med Technol; 2018 Dec; 46(4):378-383. PubMed ID: 30076246 [TBL] [Abstract][Full Text] [Related]
2. Semiautomatic region-of-interest validation at the femur in (18)F-fluoride PET/CT. Puri T; Blake GM; Curran KM; Carr H; Moore AE; Colgan N; O'Connell MJ; Marsden PK; Fogelman I; Frost ML J Nucl Med Technol; 2012 Sep; 40(3):168-74. PubMed ID: 22892275 [TBL] [Abstract][Full Text] [Related]
3. 18F-Fluoride PET/CT tumor burden quantification predicts survival in breast cancer. Brito AE; Santos A; Sasse AD; Cabello C; Oliveira P; Mosci C; Souza T; Amorim B; Lima M; Ramos CD; Etchebehere E Oncotarget; 2017 May; 8(22):36001-36011. PubMed ID: 28415595 [TBL] [Abstract][Full Text] [Related]
4. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. Etchebehere EC; Araujo JC; Fox PS; Swanston NM; Macapinlac HA; Rohren EM J Nucl Med; 2015 Aug; 56(8):1177-84. PubMed ID: 26069307 [TBL] [Abstract][Full Text] [Related]
5. Assessment of skeletal tumour burden on 18F-NaF PET/CT using a new quantitative method. Lapa P; Marques M; Costa G; Iagaru A; Pedroso de Lima J Nucl Med Commun; 2017 Apr; 38(4):325-332. PubMed ID: 28230714 [TBL] [Abstract][Full Text] [Related]
6. Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT. Rohren EM; Etchebehere EC; Araujo JC; Hobbs BP; Swanston NM; Everding M; Moody T; Macapinlac HA J Nucl Med; 2015 Oct; 56(10):1507-12. PubMed ID: 26135112 [TBL] [Abstract][Full Text] [Related]
7. Is Response Assessment of Breast Cancer Bone Metastases Better with Measurement of Azad GK; Siddique M; Taylor B; Green A; O'Doherty J; Gariani J; Blake GM; Mansi J; Goh V; Cook GJR J Nucl Med; 2019 Mar; 60(3):322-327. PubMed ID: 30042160 [TBL] [Abstract][Full Text] [Related]
8. Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer. Roop MJ; Singh B; Singh H; Watts A; Kohli PS; Mittal BR; Singh G Clin Nucl Med; 2017 May; 42(5):335-340. PubMed ID: 28263210 [TBL] [Abstract][Full Text] [Related]
9. Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer. Abikhzer G; Srour S; Fried G; Drumea K; Kozlener E; Frenkel A; Israel O; Fogelman I; Kagna O Nucl Med Commun; 2016 Nov; 37(11):1160-8. PubMed ID: 27536906 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of bone-seeking novel radiotracer Passah A; Tripathi M; Ballal S; Yadav MP; Kumar R; Roesch F; Meckel M; Sarathi Chakraborty P; Bal C Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):41-49. PubMed ID: 27455986 [TBL] [Abstract][Full Text] [Related]
12. Comparison of 18F fluoride PET/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma. Chakraborty D; Bhattacharya A; Mete UK; Mittal BR Clin Nucl Med; 2013 Aug; 38(8):616-21. PubMed ID: 23603596 [TBL] [Abstract][Full Text] [Related]
13. [Extension study and evaluation of the therapeutic response in a patient with metastatic lung adenocarcinoma using sequential study with ¹⁸F-FDG PET-CT and ¹⁸F-fluoride PET-CT]. Moragas M; Soler M; Riera E; García JR Rev Esp Med Nucl Imagen Mol; 2015; 34(1):45-8. PubMed ID: 24690280 [TBL] [Abstract][Full Text] [Related]
14. 18F-Fluoride PET/CT for detection of bone metastasis in patients with renal cell carcinoma: a pilot study. Sharma P; Karunanithi S; Chakraborty PS; Kumar R; Seth A; Julka PK; Bal C; Kumar R Nucl Med Commun; 2014 Dec; 35(12):1247-53. PubMed ID: 25171438 [TBL] [Abstract][Full Text] [Related]
15. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. Even-Sapir E; Metser U; Flusser G; Zuriel L; Kollender Y; Lerman H; Lievshitz G; Ron I; Mishani E J Nucl Med; 2004 Feb; 45(2):272-8. PubMed ID: 14960647 [TBL] [Abstract][Full Text] [Related]
16. Quantitative Assessment of Early [ Harmon SA; Perk T; Lin C; Eickhoff J; Choyke PL; Dahut WL; Apolo AB; Humm JL; Larson SM; Morris MJ; Liu G; Jeraj R J Clin Oncol; 2017 Aug; 35(24):2829-2837. PubMed ID: 28654366 [TBL] [Abstract][Full Text] [Related]
17. Burden of metastatic bone disease measured on 18F-NaF PET/computed tomography studies as a prognostic indicator in patients with medullary thyroid cancer. Ueda CE; Duarte PS; de Castroneves LA; Flávio J; Marin G; Sado HN; Sapienza MT; Hoff AO; Buchpiguel CA Nucl Med Commun; 2020 May; 41(5):469-476. PubMed ID: 32187160 [TBL] [Abstract][Full Text] [Related]
18. Accuracy of 18F-NaF PET/CT in bone metastasis detection and its effect on patient management in patients with breast carcinoma. Broos WAM; van der Zant FM; Wondergem M; Knol RJJ Nucl Med Commun; 2018 Apr; 39(4):325-333. PubMed ID: 29351123 [TBL] [Abstract][Full Text] [Related]
20. The Role of 18F-Sodium Fluoride PET/CT Bone Scans in the Diagnosis of Metastatic Bone Disease from Breast and Prostate Cancer. Kulshrestha RK; Vinjamuri S; England A; Nightingale J; Hogg P J Nucl Med Technol; 2016 Dec; 44(4):217-222. PubMed ID: 27634981 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]